Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration‐resistant prostate cancer

Published:2019-01-06 Issue:6 Volume:79 Page:567-573
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Fan Liancheng¹,Yang Yan²,Chi Chenfei¹,Ma Xiaowei³,Wang Rui⁴,Gong Yiming¹,Zheng Hongying⁵,Pan Jiahua¹,Zhu Yinjie¹,Dong Baijun¹,Xue Wei¹^ORCID

Affiliation:

1. Department of Urology, Renji Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina

2. The Second Military Medical UniversityShanghaiChina

3. Department of Clinical LaboratoryRen Ji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

4. Department of Ultrasound in MedicineShanghai Jiaotong University Affiliated Sixth People's HospitalShanghai Institute of Ultrasound in MedicineShanghaiChina

5. Department of Nurse, Ren Ji HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Funder

Science and Technology Commission of Shanghai Municipality

Shanghai Jiao Tong University

National Natural Science Foundation of China

Shanghai Municipal Education Commission

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23762

Reference29 articles.

1. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

2. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

3. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

4. Abiraterone and Increased Survival in Metastatic Prostate Cancer

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‐resistant prostate cancer progressing after docetaxel treatment: a randomised open‐label trial;de Bono JS;Lancet,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review;Frontiers in Oncology;2024-04-15

2. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15

3. Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer;Journal of Cancer Research and Clinical Oncology;2023-03-13

4. Chromogranin A: a useful biomarker in castration-resistant prostate cancer;World Journal of Urology;2022-12-17

5. Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer;Cancer Reports;2022-12-05